Immune Response has started a 32-week Phase II trial of its HIVimmunotherapeutic Remune (gp120-depleted HIV-immunogen) in combination with triple antiretroviral therapy consisting of Glaxo Wellcome's reverse transcriptase inhibitors Retrovir (zidovudine) and Epivir (lamivudine) and Merck & Co's protease inhibitor Crixivan (indinavir).
Immune Response notes that progression to AIDS seems to occur as a result of a loss of HIV-specific immunity, on which antiviral drugs have little impact. Combining antivirals and Remune, which appears to augment HIV-specific immunity, it adds, may offer synergies.
The trial will enroll 150 HIV-positive individuals with CD4 counts greater than 400/mm3.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze